Hemab Therapeutics (COAG) Stock Price, News & Analysis

Company Overview

Hemab Therapeutics is a clinical-stage biotechnology company focused on developing novel therapies for people with serious bleeding and thrombotic disorders. The company’s research is centered on treatments designed to address diseases of the blood and coagulation system, with the goal of improving outcomes for patients who may not be adequately served by existing options.

Hemab’s pipeline includes drug candidates aimed at rare hematologic conditions, including factor XI-related approaches and other programs in inherited bleeding disorders. The company’s work combines biology and translational research to advance potential therapies from discovery through clinical development.

Based on publicly available information, Hemab Therapeutics is headquartered in the United States and operates as part of the broader global biopharmaceutical industry. The company’s leadership includes a management team with experience in drug development and hematology-focused research.

Key Stats

• Today's Range: $43.05 to $46.20
• 50-Day Range: $29.97 to $54.94
• 52-Week Range: $23.00 to $55.42
• Volume: 429,283 shs
• Average Volume: 300,465 shs
• Market Capitalization: $2.08 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $51.40
• Consensus Rating: Moderate Buy

Hemab Therapeutics Stock Analysis - MarketRank™

Hemab Therapeutics scored higher than 60% of companies evaluated by MarketBeat, and ranked 325th out of 907 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Hemab Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.57, and is based on no strong buy ratings, 5 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Hemab Therapeutics has a consensus price target of $51.40, representing about 15.5% upside from its current price of $44.50.

Amount of Analyst Coverage

Hemab Therapeutics has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Hemab Therapeutics are expected to grow in the coming year, from ($3.09) to ($2.64) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Hemab Therapeutics is -1.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Hemab Therapeutics is -1.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

4.35% of the float of Hemab Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Hemab Therapeutics has a short interest ratio ("days to cover") of 6.16.

Change versus previous month

Short interest in Hemab Therapeutics has recently decreased by 0.26%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Hemab Therapeutics does not currently pay a dividend.

Dividend Growth

Hemab Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 2.8 / 5
• News Sentiment: 1.53

News Sentiment

Hemab Therapeutics has a news sentiment score of 1.53. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.75 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Hemab Therapeutics this week, compared to 3 articles on an average week.

Search Interest

Only 5 people have searched for COAG on MarketBeat in the last 30 days. This is a decrease of -17% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Hemab Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 2.9 / 5
• Insider Trading: Acquiring Shares

Net Insider Buying

Over the last three months, insiders have purchased a net $1,689,818.00 in company stock, which represents 0.0813% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, Hemab Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $1,689,818.00 in company stock and sold $0.00 in company stock.

Percentage Held by Institutions

Hemab Therapeutics has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 8/11/2026
• Today: 9/10/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:COAG
• CIK: 2114044
• Web: www.hemab.com
• Phone: (452) 138-7627
• Fax: N/A
• Employees: 72
• Year Founded: 2019

Price Target and Rating

• Average Price Target for Hemab Therapeutics: $51.40
• High Price Target: $64.00
• Low Price Target: $36.00
• Potential Upside/Downside: +15.5%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.57
• Research Coverage: 7 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 35.85
• Quick Ratio: 35.85

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 46,712,000
• Free Float: N/A
• Market Cap: $2.08 billion
• Optionable: N/A
• Beta: N/A